IQVIA, a leading provider of clinical research services and healthcare intelligence, has announced the appointment of Dr. William G. Kaelin Jr. to its Board of Directors. Kaelin currently serves as a Senior Physician at Brigham and Women’s Hospital, the Sidney Farber Professor of Medicine at Dana-Farber

Become a Member

Members have access to all articles.

Membership
Cancer Institute and Harvard Medical School, and an Investigator at the Howard Hughes Medical Institute. Recognized for his discoveries on oxygen sensing and the VHL tumor suppressor protein, Kaelin also serves on the board of Eli Lilly and Company, where he chairs the Science and Technology Committee.

Ari Bousbib, Chairman and CEO of IQVIA, stated, “I am very pleased to welcome Bill to our board of directors. Bill is a world-renowned scientist and physician with deep expertise in oncology and biomedical innovation and will be an outstanding addition to our board.” Kaelin holds an M.D. from Duke University School of Medicine and has received numerous honors, including the Albert Lasker and Canada Gairdner awards. His appointment reinforces IQVIA’s commitment to advancing innovation and improving healthcare outcomes through scientific excellence and responsible AI-driven insights.

Read more